08.18.09
Xceleron has signed a second Master Service Agreement with GlaxoSmithKline, under which Xceleron will provide analytical support to GSK and its affiliated research organizations. Also, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.
AMS allows for early investigations of the human relevancy of new drugs helping to enhance the drug discovery and development process. This second agreement is focused on the rapid analyses and data turnaround for GSK’s early clinical studies, adding to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.
Michael Butler, Ph.D., chief executive officer at Xceleron commented, “We’re just pleased that GlaxoSmithKline recognizes the value of AMS, and Xceleron’s expertise with this ultra-sensitive methodology. We’re now well-positioned to strengthen an already productive collaboration.”
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference
AMS allows for early investigations of the human relevancy of new drugs helping to enhance the drug discovery and development process. This second agreement is focused on the rapid analyses and data turnaround for GSK’s early clinical studies, adding to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.
Michael Butler, Ph.D., chief executive officer at Xceleron commented, “We’re just pleased that GlaxoSmithKline recognizes the value of AMS, and Xceleron’s expertise with this ultra-sensitive methodology. We’re now well-positioned to strengthen an already productive collaboration.”
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference